18F-fluorodeoxyglucose positron emission tomography/computed tomography and magnetic resonance imaging in patients with liver metastases from uveal melanoma: Results from a pilot study

Melanoma Research

Volumn 22, Issue 1, 2012, Pages 63-69

  Orcurto, Victoria ^a   Denys, Alban ^a   Voelter, Verena ^b   Schalenbourg, Ann ^a   Schnyder, Pierre ^a   Zografos, Leonidas ^a   Leyvraz, Serge ^b   Delaloye, Angelika Bischof ^a   Prior, John O ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

18F fluorodeoxyglucose; liver metastasis; MRI; positron emission tomography computed tomography; uveal melanoma

Indexed keywords

FLUORODEOXYGLUCOSE F 18; FOTEMUSTINE; GADODIAMIDE; GADOLINIUM PENTETATE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG UPTAKE; FEMALE; FOLLOW UP; HUMAN; LIVER INJURY; LIVER METASTASIS; LIVER PARENCHYMA; MALE; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 3 CLINICAL TRIAL; PILOT STUDY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; UVEA MELANOMA;

ADULT; AGED; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MELANOMA; MIDDLE AGED; PILOT PROJECTS; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RADIOPHARMACEUTICALS; UVEAL NEOPLASMS; YOUNG ADULT;

EID: 84855805340     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0b013e32834d3dcb     Document Type: Article

References (29)

1. Mudhar HS, Parsons MA, Sisley K, Rundle P, Singh A, Rennie IG. A critical appraisal of the prognostic and predictive factors for uveal malignant melanoma. Histopathology 2004; 45:1-12. (Pubitemid 38969556)
2. Singh AD, Topham A. Incidence of uveal melanoma in the United States: 1973-1997. Ophthalmology 2003; 110:956-961. (Pubitemid 36560496)
3. Virgili G, Gatta G, Ciccolallo L, Capocaccia R, Biggeri A, Crocetti E, et al. Incidence of uveal melanoma in Europe. Ophthalmology 2007; 114: 2309-2315.
4. Bakalian S, Marshall JC, Logan P, Faingold D, Maloney S, Di Cesare S, et al. Molecular pathways mediating liver metastasis in patients with uveal melanoma. Clin Cancer Res 2008; 14:951-956. (Pubitemid 351302538)
5. Damato B, Dopierala J, Klaasen A, Van Dijk M, Sibbring J, Coupland SE. Multiplex ligation-dependent probe amplification of uveal melanoma: correlation with metastatic death. Invest Ophthalmol. Vis. Sci. 2009; 50:3048-3055.
6. Feldman ED, Pingpank JF, Alexander HR Jr. Regional treatment options for patients with ocular melanoma metastatic to the liver. Ann Surg Oncol 2004; 11:290-297. (Pubitemid 40486769)
7. Kennedy AS, Nutting C, Jakobs T, Cianni R, Notarianni E, Ofer A, et al. A first report of radioembolization for hepatic metastases from ocular melanoma. Cancer Invest 2009; 27:682-690.
8. Kuvshinoff B, Fong Y. Surgical therapy of liver metastases. Semin Oncol 2007; 34:177-185. (Pubitemid 46874549)
9. Triozzi PL, Eng C, Singh AD. Targeted therapy for uveal melanoma. Cancer Treat Rev 2008; 34:247-258.
10. Peters S, Voelter V, Zografos L, Pampallona S, Popescu R, Gillet M, et al. Intra-arterial hepatic fotemustine for the treatment of liver metastases from uveal melanoma: experience in 101 patients. Ann Oncol 2006; 17: 578-583.
11. Reddy S, Kurli M, Tena LB, Finger PT. PET/CT imaging: detection of choroidal melanoma. Br J Ophthalmol 2005; 89:1265-1269. (Pubitemid 41638862)
12. Kurli M, Reddy S, Tena LB, Pavlick AC, Finger PT. Whole body positron emission tomography/computed tomography staging of metastatic choroidal melanoma. Am J Ophthalmol 2005; 140: 193-199.
13. Francken AB, Fulham MJ, Millward MJ, Thompson JF. Detection of metastatic isease in patients with uveal melanoma using positron emission tomography. Eur J Surg Oncol 2006; 32:780-784. (Pubitemid 44276011)
14. Beyer T, Pietrzyk U, Knoess C, Vollmar S, Wienhard K, Kracht L, et al. Multi-modality imaging of uveal melanomas using combined PET/CT, high-resolution PET and MR imaging. Nuklearmedizin 2008; 47:73-79. (Pubitemid 351700465)
15. Servois V, Mariani P, Malhaire C, Petras S, Piperno-Neumann S, Plancher C, et al. Preoperative staging of liver metastases from uveal melanoma by magnetic resonance imaging (MRI) and fluorodeoxyglucose-positron emission tomography (FDG-PET). Eur J Surg Oncol 2010; 36:189-194.
16. Weber WA, Ziegler SI, Thodtmann R, Hanauske AR, Schwaiger M. Reproducibility of metabolic measurements in malignant tumors using FDG PET. J Nucl Med 1999; 40:1771-1777. (Pubitemid 29523568)
17. Aoyama T, Mastrangelo MJ, Berd D, Nathan FE, Shields CL, Shields JA, et al. Protracted survival after resection of metastatic uveal melanoma. Cancer 2000; 89:1561-1568.
18. Van Raamsdonk CD, Griewank KG, Crosby MB, Garrido MC, Vemula S, Wiesner T, et al. Mutations in GNA11 in uveal melanoma. N Engl J Med 2010; 363:2191-2199.
19. Leyvraz S, Spataro V, Bauer J, Pampallona S, Salmon R, Dorval T, et al. Treatment of ocular melanoma metastatic to the liver by hepatic arterial chemotherapy. J Clin Oncol 1997; 15:2589-2595. (Pubitemid 27289889)
20. Maeda T, Tateishi U, Suzuki S, Arai Y, Kim EE, Sugimura K. Magnetic resonance screening trial for hepatic metastasis in patients with locally controlled choroidal melanoma. Jpn J Clin Oncol 2007; 37: 282-286. (Pubitemid 47090680)
21. Soret M, Bacharach SL, Buvat I. Partial-volume effect in PET tumor imaging. J Nucl Med 2007; 48:932-945. (Pubitemid 46909922)
22. Bolard G, Prior JO, Modolo L, Delaloye AB, Kosinski M, Wastiel C, et al. Performance comparison of two commercial BGO-based PET/CT scanners using NEMA NU 2-2001. Med Phys 2007; 34:2708-2717. (Pubitemid 47019793)
23. American Joint Committee on Cancer. Malignant melanoma of the uvea AJCC Cancer Staging Manual. 6th edn. New York, NY: Springer. 2002; pp. 365-370.
24. Strobel K, Bode B, Dummer R, Veit-Haibach P, Fischer D, Imhof L, et al. Limited value of 18F-FDG PET/CT and S-100B tumour marker in the detection of liver metastases from uveal melanoma compared to liver metastases from cutaneous melanoma. Eur J Nucl Med Mol Imaging 2009; 36:1774-1782.
25. Larson SM, Schwartz LH. 18F-FDG PET as a candidate for 'qualified biomarker': functional assessment of treatment response in oncology. J Nucl Med 2006; 47:901-903. (Pubitemid 46939939)
26. Prior JO, Montemurro M, Orcurto MV, Michielin O, Luthi F, Benhattar J, et al. Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor. J Clin Oncol 2009; 27:439-445.
27. Downey RJ, Akhurst T, Gonen M, Vincent A, Bains MS, Larson S, et al. Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. J Clin Oncol 2004; 22:3255-3260. (Pubitemid 41103680)
28. Shankar LK, Hoffman JM, Bacharach S, Graham MM, Karp J, Lammertsma AA, et al. Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute trials. J Nucl Med 2006; 47:1059-1066. (Pubitemid 46939960)
29. Buijs M, Vossen JA, Hong K, Georgiades CS, Geschwind JF, Kamel IR. Chemoembolization of hepatic metastases from ocular melanoma: assessment of response with contrast-enhanced and diffusionweighted MRI. AJR Am J Roentgenol 2008; 191:285-289. (Pubitemid 351955216)